Freising, Germany

Shane Olwill

USPTO Granted Patents = 15 

 

 

Average Co-Inventor Count = 5.6

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Friesing-Weihenstephan, DE (2018)
  • Freising-Weihenstephan, DE (2021)
  • Freising, DE (2019 - 2024)

Company Filing History:


Years Active: 2018-2025

Loading Chart...
Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents

Title: Inventor Shane Olwill: Pioneering Advances in Cancer Treatment

Introduction: Shane Olwill is a prominent inventor based in Freising, Germany, known for his significant contributions to the field of pharmaceutical innovations. With an impressive portfolio of 15 patents, Olwill’s work primarily focuses on developing targeted therapies related to cancer treatment.

Latest Patents: One of Shane Olwill's latest patents involves "Proteins specific for CD137." This innovation provides human lipocalin muteins that bind to CD137, paving the way for their use in pharmaceutical applications, such as anti-cancer agents and immune modulators. These lipocalin muteins hold promise for treating or preventing a range of human diseases, including cancer, infectious diseases, and autoimmune disorders. The patent also outlines methods for creating these CD137 binding lipocalin muteins and includes information about nucleic acid molecules that encode them.

Another key patent by Olwill is the development of an "Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)." This fusion polypeptide is significant for its ability to direct CD137 clustering and activation specifically at GPC3-positive tumor cells. The applications of this fusion polypeptide extend to various pharmaceutical contexts, serving as anti-cancer agents or immune modulators. Similar to his previous inventions, this patent includes methods for generating the fusion polypeptide and related nucleic acid molecules, as well as outlining therapeutic and diagnostic applications.

Career Highlights: Throughout his career, Shane Olwill has been associated with notable companies such as Pieris Pharmaceuticals GmbH and Pieris Australia Pty Ltd. His work in these organizations reflects his commitment to advancing medical science and addressing critical health challenges.

Collaborations: Shane has collaborated with talented individuals throughout his career, including Rachida Siham Bel Aiba and Christine Rothe. His teamwork with these professionals has undoubtedly contributed to the innovation of effective therapeutic solutions.

Conclusion: Shane Olwill's remarkable contributions to the field of cancer treatment through his patents and collaborations highlight his role as a leading inventor in the pharmaceutical industry. With ongoing efforts to develop targeted therapies, his work continues to inspire progress in medical research and innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…